DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Tebipenem pivoxil

Generic Name: Tebipenem pivoxil

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₃₁N_₃O_₆S_₂

CAS Number: 161715-24-8

Unique Ingredient Identifier: 95AK1A52I8

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite (SPR1349) in Healthy Participants

Phase 1

Completed

Posted: 2024/12/10

Sponsor:Spero Therapeutics

A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Phase 3

Recruiting

Posted: 2023/09/29

Sponsor:Spero Therapeutics

A Study to Compare Two Bioanalytical Assays for Tebipenem

Phase 1

Completed

Posted: 2023/05/12

Sponsor:Spero Therapeutics

Tebipenem Trial in Children With Shigellosis

Phase 2

Recruiting

Posted: 2021/11/16

Sponsor:International Centre...

Tebipenem (SPR994) Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

Phase 1

Completed

Posted: 2021/06/09

Sponsor:Hartford Hospital

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Advancements in Complicated Urinary Tract Infection (cUTI) Therapeutics

6 months ago

Several pharmaceutical and biotech companies are actively developing novel therapies for complicated urinary tract infections (cUTIs).

Spero Therapeutics Investor Lawsuit Dismissed Over FDA Feedback on Tebipenem

7 months ago

A federal court dismissed a proposed class action lawsuit against Spero Therapeutics by investors regarding statements about a clinical trial and FDA approval prospects.

Spero Therapeutics Investor Lawsuit Dismissed Over FDA Approval Statements

7 months ago

A federal court dismissed a proposed class action lawsuit against Spero Therapeutics by investors regarding statements about a clinical trial and FDA approval prospects.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy